NFA
AKBA icon

Nationwide Fund Advisors’s Akebia Therapeutics AKBA Stock Holding History

Nationwide Fund Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-23,765
Closed -$467K – 73
2017
Q3 		$467K Buy
23,765
+2,362
+11% +$36.3K ﹤0.01% 2219
2017
Q2 		$308K Buy
21,403
+915
+4% +$11.6K ﹤0.01% 2435
2017
Q1 		$188K Sell
20,488
-2,937
-13% -$28.7K ﹤0.01% 2618
2016
Q4 		$244K Buy
23,425
+1,429
+6% +$12.3K ﹤0.01% 2516
2016
Q3 		$199K Buy
21,996
+1,059
+5% +$9K ﹤0.01% 2623
2016
Q2 		$157K Hold
20,937
– – ﹤0.01% 2724
2016
Q1 		$189K Buy
20,937
+5,013
+31% +$40.6K ﹤0.01% 2557
2015
Q4 		$206K Buy
15,924
+474
+3% +$4.84K ﹤0.01% 2537
2015
Q3 		$149K Hold
15,450
– – ﹤0.01% 2719
2015
Q2 		$159K Buy
15,450
+9,870
+177% +$84.2K ﹤0.01% 2824
2015
Q1 		$62K Sell
5,580
-28,706
-84% -$306K ﹤0.01% 3063
2014
Q4 		$399K Buy
34,286
+28,312
+474% +$406K ﹤0.01% 2316
2014
Q3 		$132K Buy
5,974
+3
+0.1% +$69 ﹤0.01% 2885
2014
Q2 		$166K Buy
+5,971
New +$144K ﹤0.01% 2838

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Nationwide Fund Advisors's AKBA Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Akebia Therapeutics (AKBA) in Q4 2017, closing a stake of 23,765 shares — an estimated $467K sold.

Nationwide Fund Advisors first reported a position in AKBA in Q2 2014 and held it in 14 quarters. The position peaked at $467K in Q3 2017. 132 funds tracked by Wall St. Rank hold AKBA as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Akebia Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 23,765 Akebia Therapeutics shares in Q4 2017, an estimated $467K.
  • Nationwide Fund Advisors first reported a position in Akebia Therapeutics in Q2 2014 and held it in 14 quarters.
  • Nationwide Fund Advisors's Akebia Therapeutics position peaked at $467K in Q3 2017.
  • 132 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.